Determination of polymeric impurities in asunaprevir drug substance and product using size exclusion effect of reversed-phase columns

被引:5
作者
Huang, Zongyun [1 ]
Hu, Yue [1 ]
Zha, Yan [1 ]
Perrone, Robert [1 ]
Ruan, Joan [1 ]
Fish, William P. [1 ]
机构
[1] Bristol Myers Squibb, Drug Prod Sci & Technol, 1 Squibb Dr, New Brunswick, NJ 08901 USA
关键词
HPLC; Impurity; Polymer quantitation; Sample treatment; Drug product; Size exclusion; LIQUID-CHROMATOGRAPHY; ELUTION CHROMATOGRAPHY; SYNTHETIC-POLYMERS; RETENTION BEHAVIOR; PARAMETERS; ADSORPTION;
D O I
10.1016/j.jpba.2018.01.018
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
This paper describes the development of a simple reversed-phase HPLC method that can quantitate trace amounts of a polymeric degradants (BMT-041910) in asunaprevir drug substance and formulated drug product with quantitation limits of similar to 0.05% w/w. The method has overcome several challenges of polymer quantitation such as band broadening, peak coeluting and low sensitivity. The hydrophobic function group (BOC) of BMT-041910 is removed to increase its aqueous solubility by a simple sample treatment procedure (des-BOC). The des-BOC polymer (BMT-052076) is excluded from stationary phase pores and eluted as a single peak before solvent front, and then its peak area response can be used to determine BMT-041910 amount. The HPLC conditions were optimized using a 250 x 4.6 mm Waters XSelect CSH column maintained at 30 degrees C with a mobile phase of water-acetonitrile-trifluoroacetic acid (20:80:0.1 v/v/v). The feasibility of other HPLC approaches including size exclusion chromatography and normal phase chromatography were also investigated and found to be less suitable for this particular application. Validation data for this method in terms of precision, linearity, accuracy and sensitivity are also presented. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:200 / 208
页数:9
相关论文
共 18 条